safinamide has been researched along with zonisamide in 4 studies
| Studies (safinamide) | Trials (safinamide) | Recent Studies (post-2010) (safinamide) | Studies (zonisamide) | Trials (zonisamide) | Recent Studies (post-2010) (zonisamide) |
|---|---|---|---|---|---|
| 199 | 29 | 159 | 922 | 121 | 382 |
| Protein | Taxonomy | safinamide (IC50) | zonisamide (IC50) |
|---|---|---|---|
| Carbonic anhydrase 12 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 2 | Bos taurus (cattle) | 1.86 | |
| Carbonic anhydrase 3 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 4 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 6 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 7 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 13 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 14 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | 1.86 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhowmick, SS; Fox, SH; Gonzalez-Latapi, P; Saranza, G | 1 |
| Jing, XZ; Luo, X; Wang, XP; Yuan, XZ; Zhang, SY | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
| Abou-Setta, A; Aboulatta, L; Askin, N; Eltonsy, S; Haidar, L; Lavu, A; Peymani, P; Rabbani, R; Zarychanski, R | 1 |
4 review(s) available for safinamide and zonisamide
| Article | Year |
|---|---|
Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Development; Drug Repositioning; Humans; Parkinson Disease; Purines; Zonisamide | 2020 |
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
Topics: Antiparkinson Agents; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Serotonin; Zonisamide | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Dopamine Agents; Humans; Monoamine Oxidase; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Zonisamide | 2023 |